Back to Search
Start Over
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus.
- Source :
-
New England Journal of Medicine . 10/3/2013, Vol. 369 Issue 14, p1317-1326. 10p. - Publication Year :
- 2013
-
Abstract
- The article presents a study which examines the safety and efficacy of saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, in the cardiovascular outcomes of patients with type 2 diabetes mellitus. Samples include 16,492 patients who had history of cardiovascular events were randomly assigned to administer saxagliptin or placebo. Results show that a primary end point occurred in 609 patients assigned to placebo and in 613 patients assigned to saxagliptin.
Details
- Language :
- English
- ISSN :
- 00284793
- Volume :
- 369
- Issue :
- 14
- Database :
- Academic Search Index
- Journal :
- New England Journal of Medicine
- Publication Type :
- Academic Journal
- Accession number :
- 91752672
- Full Text :
- https://doi.org/10.1056/NEJMoa1307684